Mouse monoclonal antibody raised against full length recombinant human CDKN1B.
Recombinant protein corresponding to full length human CDKN1B.
Theoretical MW (kDa):
This monoclonal antibody is highly specific to CDKN1B and shows no cross-reaction with other closely related mitotic inhibitors.
Protein A/G purification
Flow Cytometry (0.5-1 ug/106 cells in 0.1 mL) Immunofluorescence (0.5-1 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (0.25-0.5 ug/mL) Western Blot (0.5-1 ug/mL) The optimal working dilution should be determined by the end user.
In 10 mM PBS (0.05% BSA, 0.05% sodium azide).
Store at 4°C.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Immunohistochemical staining (Formalin-fixed paraffin-embedded sections) of human colon carcinoma (A), human prostate cancer (B), human cervical cancer (C) and rat colon (D) with CDKN1B monoclonal antibody, clone KIP1/769 (Cat # MAB13245).
Flow cytometric analysis of Jurkat cells with CDKN1B monoclonal antibody, clone KIP1/769 (Cat # MAB13245). Black: Cells alone; Grey: Isotype control; Green: AF488 conjugated format of CDKN1B monoclonal antibody, clone KIP1/769.
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. [provided by RefSeq